Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.
- cell- and tissue-based therapy
- chronic heart failure
- clinical trial
- heart disease
- mesenchymal stem cells
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine